ClinicalTrials.gg
CompletedNCT00108082Updated Dec 16, 2016Results posted

The CLEVER Study - Coreg And Left Ventricular Mass Regression

A Phase 3 interventional study of carvedilol MR and atenolol in Hypertrophy, Left Ventricular, sponsored by GlaxoSmithKline. Completed at 78 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2016-12-16.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
287
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies in Hypertrophy, Left Ventricular with a site in United States — 7 open to participants now, 8 under way, none of them phase 3. Hypertrophy, Left Ventricular · United States.

Enrollment
4th of 26
287 · median 94
Started
2005
with 2 others
Phase 3
5 of 38
none open now
Registered
5th of 38
by date

Among the 38 studies in Hypertrophy, Left Ventricular with a site in United States, this one is the 4th largest by enrollment of the 26 interventional ones that give a count, is one of 3 that started in 2005, is one of 5 in phase 3, and was the 5th registered.

Hypertrophy, Left Ventricular

162 studies on the registry are indexed under Hypertrophy, Left Ventricular; 28 are open to participants now.

Browse Hypertrophy, Left Ventricular studies →

Open to participants now

7 of the 38 studies in Hypertrophy, Left Ventricular with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Hypertrophy, Left Ventricular studies recruiting now, 13 (65%) set no upper age limit and 2 (10%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Hypertrophy, Left Ventricular with a site in United States, or all of them as a file.
02

Study summary

This study is designed to compare the effects of COREG MR (carvedilol modified release formulation) to atenolol on indices of left ventricular dimensions when added to standardized angiotensin converting enzyme (ACE) inhibition, and to the effect of ACE inhibition alone. Subjects with LVH (left ventricular hypertrophy) and hypertension will be studied. The primary endpoint will be the change in left ventricular mass index (LVMI) characterized by magnetic resonance imaging (MRI) following 12 months of treatment. Secondary endpoints include the change in LV (left ventricular) mass, LV wall thickness, diastolic left ventricular filling parameters, and left ventricular ejection fraction by echocardiographic methods at Treatment Month 12. Composite outcomes and individual event data will also be evaluated by treatment group.

Read the detailed description

A Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Carvedilol Modified Release Formulation (COREG MR) and Atenolol in Combination with and Compared to an Angiotensin Converting Enzyme Inhibitor (Lisinopril) on Left Ventricular Mass Regression in Hypertensive Patients with Left Ventricular Hypertrophy (LVH).

03

Conditions studied

  • Hypertrophy, Left Ventricular

Keywords

  • left ventricular hypertrophy (LVH)
  • echocardiogram
  • left ventricular mass regression
  • cardiac MRI
  • left ventricular mass index (LVMI)hypertension
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Stage 1 or Stage 2 hypertension.
  • Left ventricular hypertrophy.

Exclusion criteria

Exclusion criteria:

  • In atrial fibrillation.
  • Takes beta-blocker for MI (myocardial infarction) or arrhythmia.
  • Has uncontrolled diabetes, uncontrollable or symptomatic arrhythmias, unstable angina, second or third degree heart block, history of MI, (chronic obstructive pulmonary disease), liver or kidney disease.
  • Uses beta-2-agonists.
  • Unable to undergo MRI (magnetic resonance imaging).
  • Females of .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
287 participants (actual)

Study arms

  • Experimental
    Carvedilol CR

    Carvedilol controlled release (CR) 20 to 80 mg once daily (OD) plus lisinopril 20 mg OD. Participants were titrated from the starting dosage to higher dosages until their blood pressure was controlled. Participants continued to receive lisinopril 20 mg OD throughout the study. (In the protocol, carvedilol CR was referred to as carvedilol modified-release \[MR\].)

    Drug: carvedilol MR · Drug: lisinopril

  • Experimental
    Atenolol

    Atenolol 50 to 100 mg OD plus lisinopril 20 mg OD. Participants were titrated from the starting dosage to higher dosages until their blood pressure was controlled. Participants continued to receive lisinopril 20 mg OD throughout the study.

    Drug: atenolol · Drug: lisinopril

  • Experimental
    Lisinopril

    Lisinopril 10 to 40 mg OD plus lisinopril 20 mg OD. Participants were titrated from the starting dosage to higher dosages until their blood pressure was controlled. Participants continued to receive lisinopril 20 mg OD throughout the study.

    Drug: lisinopril

Interventions

  • Study drug

    Also known as: Carvedilol controlled release or modified release

  • Comparator

  • Comparator

    Also known as: carvedilol MR, atenolol

06

What researchers measure

Primary outcomes

  1. Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed (LVMI) by Body Surface Area as Measured by Magnetic Resonance Imaging (MRI) at Month 12

    LVMI was measured by MRI at Baseline and after 12 months of treatment/Month 12. A reduction in left ventricular mass, calculated as LVMI, of 5 g/m\^2 was assumed to be clinically meaningful. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.

    Time frame: Baseline and Month 12 (If Month 12 data were not available, the Last Observation Carried Forward [LOCF] analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)

Secondary outcomes

  1. Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed by Height (LVMIH) as Measured by MRI at Month 12

    LVMIH was measured by MRI at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. LV mass depends on body size. One method of determining whether an individual has LV hypertrophy relates LV mass to height raised to a power of 2.7.

    Time frame: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)

  2. Model-adjusted Mean Change From Baseline in Left Ventricular (LV) Mass as Measured by MRI at Month 12

    LV Mass was measured by MRI at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.

    Time frame: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)

  3. Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed (LVMI) by Body Surface Area as Measured by Echocardiography at Month 12

    LVMI was measured by echogradiography at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.

    Time frame: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)

  4. Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed by Height (LVMIH) as Measured by Echocardiography at Month 12

    LVMIH was measured by echogradiography at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.

    Time frame: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was available)

  5. Model-adjusted Mean Change From Baseline in LV Mass as Measured by Echocardiography at Month 12

    LV Mass was measured by echocardiography at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.

    Time frame: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)

  6. Mean Change From Baseline in LV Filling Parameters as Measured by MRI at Month 12

    LV filling parameters, LV E-Volume and LV A-Volume, were measured by MRI at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. These filling parameters represent the volumes of blood filling the ventricle during the passive filling phase (E-volume) and the active filling phase caused by atrial contraction (A-volume).

    Time frame: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)

  7. Model-adjusted Mean Change From Baseline in LV End Systolic and Diastolic Volumes and Ejection Fraction as Measured by MRI at Month 12

    LV End Systolic and Diastolic Volumes and Ejection Fraction were measured by MRI at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. The ejection fraction is the fraction of the blood volume available at the end of diastole that is pumped out of the ventricules during systole.

    Time frame: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)

  8. Model-adjusted Mean Change From Baseline in LV End Systolic and Diastolic Volumes and Ejection Fraction as Measured by Echocardiography at Month 12

    LV End Systolic and Diastolic Volumes and Ejection Fraction were measured by echocardiography at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.

    Time frame: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)

  9. Model-adjusted Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) at Month 12

    Systolic and Diastolic BP were measured at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.

    Time frame: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)

  10. Model-adjusted Ratio to Baseline as Percentage Change From Baseline in Log Transformed B-type Natriuretic Peptide (BNP) at Month 12

    BNP concentration (picagram per milliter) was measured at Baseline and after 12 months of treatment/Month 12. Percentage change from Baseline was based on log transformed data and was calculated as 100 x (exponent (mean change on log scale) -1) \[Change is the Month 12 value (or value after 12 months of treatment) minus the Baseline value\].

    Time frame: Baseline and Month 12 (If Month 12 data were not available, the LOCF was used

  11. Model-adjusted Ratio to Baseline as Percentage Change From Baseline in Log Transformed C-Reactive Protein (CRP) at Month 12

    CRP concentration (milligrams per deciliter) was measured at Baseline and after 12 months of treatment/Month 12. Percentage change from Baseline was based on log transformed data and calculated as 100 x (exponent (mean change on log scale) - 1). \[Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.\]

    Time frame: Baseline and Month 12 (If Month 12 data were not available, the LOCF was used)

  12. Percentage Change From Baseline in Log Transformed Lipid Parameters at Month 12

    Plasma lipid concentrations (milligrams per deciliter) were measured at Baseline and after 12 months of treatment/Month 12. Percentage change from Baseline was based on log transformed data and calculated as 100 x (exponent(mean change on log scale) - 1). \[Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.\]

    Time frame: Baseline and Month 12 (If Month 12 data were not available, the LOCF was used)

  13. Model-adjusted Ratio to Baseline as Percentage Change From Baseline in Log Transformed Albumin Creatinine Ratio (ACR) at Month 12

    Urinary ACR (micrograms per milligram) was determined at Baseline and after 12 months of treatment/Month 12. Percentage change from Baseline was based on log transformed data and was calculated as 100 x (exponent (exponent (mean change on log scale) - 1. \[Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.\]

    Time frame: Baseline and Month 12 (If Month 12 data were not available, the LOCF was used)

07

Results

Posted Nov 9, 2009

Participant flow

Participant flow — Overall Study
MilestoneCarvedilol CRAtenololLisinopril
Started9110096
Completed536853
Not completed383243
Withdrew: Adverse event141217
Withdrew: Lost to follow-up637
Withdrew: Consent withdrawn335
Withdrew: Protocol violation120
Withdrew: Lack of efficacy312
Withdrew: Amendment 4: > month 12575
Withdrew: Woman of child-bearing potential202
Withdrew: Incorrectly randomized002
Withdrew: Non-compliance102
Withdrew: Stopped study medication001
Withdrew: Site closed study020
Withdrew: Protocol amendment010
Withdrew: Study medication not tapered010
Withdrew: Subject left site location100
Withdrew: Investigator not at site100
Withdrew: Blood pressure not controlled100

Outcome measures

PrimaryModel-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed (LVMI) by Body Surface Area as Measured by Magnetic Resonance Imaging (MRI) at Month 12

LVMI was measured by MRI at Baseline and after 12 months of treatment/Month 12. A reduction in left ventricular mass, calculated as LVMI, of 5 g/m\^2 was assumed to be clinically meaningful. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.

Time frame:
Baseline and Month 12 (If Month 12 data were not available, the Last Observation Carried Forward [LOCF] analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)
Reported as:
Mean · grams per meters squared (g/m^2)
Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed (LVMI) by Body Surface Area as Measured by Magnetic Resonance Imaging (MRI) at Month 12
grams per meters squared (g/m^2)Carvedilol CRAtenololLisinopril
Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed (LVMI) by Body Surface Area as Measured by Magnetic Resonance Imaging (MRI) at Month 12-6.34 ± 0.850-6.67 ± 0.756-7.94 ± 0.850
Statistical analysis
  • Carvedilol CR vs Atenolol · ANCOVA · p = 0.7651 · Mean difference (final values): 0.33 · 95% CI -1.83 to 2.49
  • Carvedilol CR vs Lisinopril · ANCOVA · p = 0.1711 · Mean difference (final values): 1.60 · 95% CI -0.70 to 3.90
SecondaryModel-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed by Height (LVMIH) as Measured by MRI at Month 12

LVMIH was measured by MRI at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. LV mass depends on body size. One method of determining whether an individual has LV hypertrophy relates LV mass to height raised to a power of 2.7.

Time frame:
Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)
Reported as:
Mean · g/m raised to 2.7 (g/(m^2.7))
Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed by Height (LVMIH) as Measured by MRI at Month 12
g/m raised to 2.7 (g/(m^2.7))Carvedilol CRAtenololLisinopril
Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed by Height (LVMIH) as Measured by MRI at Month 12-3.19 ± 0.407-3.37 ± 0.361-3.98 ± 0.407
SecondaryModel-adjusted Mean Change From Baseline in Left Ventricular (LV) Mass as Measured by MRI at Month 12

LV Mass was measured by MRI at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.

Time frame:
Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)
Reported as:
Mean · grams (g)
Model-adjusted Mean Change From Baseline in Left Ventricular (LV) Mass as Measured by MRI at Month 12
grams (g)Carvedilol CRAtenololLisinopril
Model-adjusted Mean Change From Baseline in Left Ventricular (LV) Mass as Measured by MRI at Month 12-13.74 ± 1.732-14.17 ± 1.540-17.17 ± 1.734
SecondaryModel-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed (LVMI) by Body Surface Area as Measured by Echocardiography at Month 12

LVMI was measured by echogradiography at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.

Time frame:
Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)
Reported as:
Mean · grams per meters squared (g/m^2)
Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed (LVMI) by Body Surface Area as Measured by Echocardiography at Month 12
grams per meters squared (g/m^2)Carvedilol CRAtenololLisinopril
Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed (LVMI) by Body Surface Area as Measured by Echocardiography at Month 12-20.35 ± 4.027-20.06 ± 3.672-18.48 ± 3.998
SecondaryModel-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed by Height (LVMIH) as Measured by Echocardiography at Month 12

LVMIH was measured by echogradiography at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.

Time frame:
Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was available)
Reported as:
Mean · g/m raised to 2.7 (g/(m^2.7))
Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed by Height (LVMIH) as Measured by Echocardiography at Month 12
g/m raised to 2.7 (g/(m^2.7))Carvedilol CRAtenololLisinopril
Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed by Height (LVMIH) as Measured by Echocardiography at Month 12-11.78 ± 2.292-12.51 ± 2.100-11.61 ± 2.280
SecondaryModel-adjusted Mean Change From Baseline in LV Mass as Measured by Echocardiography at Month 12

LV Mass was measured by echocardiography at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.

Time frame:
Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)
Reported as:
Mean · grams
Model-adjusted Mean Change From Baseline in LV Mass as Measured by Echocardiography at Month 12
gramsCarvedilol CRAtenololLisinopril
Model-adjusted Mean Change From Baseline in LV Mass as Measured by Echocardiography at Month 12-45.76 ± 8.338-40.56 ± 7.645-38.58 ± 8.296
SecondaryMean Change From Baseline in LV Filling Parameters as Measured by MRI at Month 12

LV filling parameters, LV E-Volume and LV A-Volume, were measured by MRI at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. These filling parameters represent the volumes of blood filling the ventricle during the passive filling phase (E-volume) and the active filling phase caused by atrial contraction (A-volume).

Time frame:
Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)
Reported as:
Mean · milliliters (mL)
Mean Change From Baseline in LV Filling Parameters as Measured by MRI at Month 12
milliliters (mL)Carvedilol CRAtenololLisinopril
LV E-volume0.364 ± 2.28536.763 ± 2.3870-3.406 ± 2.8779
LV A-volume-0.513 ± 1.3624-0.565 ± 1.51541.088 ± 1.5630
SecondaryModel-adjusted Mean Change From Baseline in LV End Systolic and Diastolic Volumes and Ejection Fraction as Measured by MRI at Month 12

LV End Systolic and Diastolic Volumes and Ejection Fraction were measured by MRI at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. The ejection fraction is the fraction of the blood volume available at the end of diastole that is pumped out of the ventricules during systole.

Time frame:
Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)
Reported as:
Mean · milliliters (mL)
Model-adjusted Mean Change From Baseline in LV End Systolic and Diastolic Volumes and Ejection Fraction as Measured by MRI at Month 12
milliliters (mL)Carvedilol CRAtenololLisinopril
LV End Systolic Volume-1.44 ± 1.578-4.29 ± 1.397-3.04 ± 1.581
LV End Diastolic Volume-2.86 ± 2.848-2.45 ± 2.522-7.45 ± 2.858
LV Ejection Fraction0.08 ± 0.6852.16 ± 0.607-0.01 ± 0.685
SecondaryModel-adjusted Mean Change From Baseline in LV End Systolic and Diastolic Volumes and Ejection Fraction as Measured by Echocardiography at Month 12

LV End Systolic and Diastolic Volumes and Ejection Fraction were measured by echocardiography at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.

Time frame:
Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)
Reported as:
Mean · milliliters (mL)
Model-adjusted Mean Change From Baseline in LV End Systolic and Diastolic Volumes and Ejection Fraction as Measured by Echocardiography at Month 12
milliliters (mL)Carvedilol CRAtenololLisinopril
LV End Systolic Volume-3.38 ± 2.067-4.74 ± 1.892-5.34 ± 2.086
LV End Diastolic Volume-3.07 ± 3.389-3.64 ± 3.108-9.37 ± 3.420
LV Ejection Fraction1.03 ± 0.7512.33 ± 0.6870.63 ± 0.756
SecondaryModel-adjusted Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) at Month 12

Systolic and Diastolic BP were measured at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.

Time frame:
Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)
Reported as:
Mean · mmHg (millimeters of mercury)
Model-adjusted Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) at Month 12
mmHg (millimeters of mercury)Carvedilol CRAtenololLisinopril
Systolic blood pressure-21.32 ± 1.755-21.12 ± 1.535-22.53 ± 1.708
Diastolic blood pressure-12.77 ± 1.103-14.05 ± 0.976-11.13 ± 1.117
SecondaryModel-adjusted Ratio to Baseline as Percentage Change From Baseline in Log Transformed B-type Natriuretic Peptide (BNP) at Month 12

BNP concentration (picagram per milliter) was measured at Baseline and after 12 months of treatment/Month 12. Percentage change from Baseline was based on log transformed data and was calculated as 100 x (exponent (mean change on log scale) -1) \[Change is the Month 12 value (or value after 12 months of treatment) minus the Baseline value\].

Time frame:
Baseline and Month 12 (If Month 12 data were not available, the LOCF was used
Reported as:
Geometric mean · percentage of change
Model-adjusted Ratio to Baseline as Percentage Change From Baseline in Log Transformed B-type Natriuretic Peptide (BNP) at Month 12
percentage of changeCarvedilol CRAtenololLisinopril
Model-adjusted Ratio to Baseline as Percentage Change From Baseline in Log Transformed B-type Natriuretic Peptide (BNP) at Month 1251.7 (13.2 to 103.2)48.3 (13.0 to 94.7)-39.1 (-54.3 to -19.0)
SecondaryModel-adjusted Ratio to Baseline as Percentage Change From Baseline in Log Transformed C-Reactive Protein (CRP) at Month 12

CRP concentration (milligrams per deciliter) was measured at Baseline and after 12 months of treatment/Month 12. Percentage change from Baseline was based on log transformed data and calculated as 100 x (exponent (mean change on log scale) - 1). \[Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.\]

Time frame:
Baseline and Month 12 (If Month 12 data were not available, the LOCF was used)
Reported as:
Geometric mean · percentage of change
Model-adjusted Ratio to Baseline as Percentage Change From Baseline in Log Transformed C-Reactive Protein (CRP) at Month 12
percentage of changeCarvedilol CRAtenololLisinopril
Model-adjusted Ratio to Baseline as Percentage Change From Baseline in Log Transformed C-Reactive Protein (CRP) at Month 12-10.63 (-27.41 to 10.02)-3.22 (-18.82 to 15.38)2.70 (-15.88 to 25.37)
SecondaryPercentage Change From Baseline in Log Transformed Lipid Parameters at Month 12

Plasma lipid concentrations (milligrams per deciliter) were measured at Baseline and after 12 months of treatment/Month 12. Percentage change from Baseline was based on log transformed data and calculated as 100 x (exponent(mean change on log scale) - 1). \[Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.\]

Time frame:
Baseline and Month 12 (If Month 12 data were not available, the LOCF was used)
Reported as:
Geometric mean · percentage of change
Percentage Change From Baseline in Log Transformed Lipid Parameters at Month 12
percentage of changeCarvedilol CRAtenololLisinopril
Total cholesterol0.7 (-3.3 to 4.9)-1.3 (-4.7 to 2.3)-1.7 (-5.5 to 2.3)
Low-density lipid cholesterol0.0 (-6.5 to 7.0)-4.0 (-9.6 to 1.8)-2.7 (-9.0 to 4.1)
High-density lipid cholesterol-4.3 (-7.7 to 0.7)-4.7 (-7.7 to -1.6)-1.5 (-4.9 to 2.1)
Triglycerides11.0 (2.0 to 20.9)7.1 (-0.7 to 15.4)6.2 (-2.4 to 15.5)
SecondaryModel-adjusted Ratio to Baseline as Percentage Change From Baseline in Log Transformed Albumin Creatinine Ratio (ACR) at Month 12

Urinary ACR (micrograms per milligram) was determined at Baseline and after 12 months of treatment/Month 12. Percentage change from Baseline was based on log transformed data and was calculated as 100 x (exponent (exponent (mean change on log scale) - 1. \[Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.\]

Time frame:
Baseline and Month 12 (If Month 12 data were not available, the LOCF was used)
Reported as:
Geometric mean · percentage of change
Model-adjusted Ratio to Baseline as Percentage Change From Baseline in Log Transformed Albumin Creatinine Ratio (ACR) at Month 12
percentage of changeCarvedilol CRAtenololLisinopril
Model-adjusted Ratio to Baseline as Percentage Change From Baseline in Log Transformed Albumin Creatinine Ratio (ACR) at Month 12-27.1 (-39.9 to -11.6)-20.1 (-32.4 to -5.5)-21.5 (-35.2 to -4.8)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Carvedilol CR———
Atenolol———
Lisinopril———
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventCarvedilol CRAtenololLisinopril
Atrial fibrillationCardiac disorders1/910/1002/96
DizzinessNervous system disorders0/910/1002/96
Transient ischemic attackNervous system disorders0/910/1002/96
Non-cardiac chest painGeneral disorders0/912/1001/96
Coronary artery diseaseCardiac disorders1/910/1000/96
DepressionPsychiatric disorders1/910/1000/96
Neuropathy peripheralNervous system disorders1/910/1000/96
Abdominal painGastrointestinal disorders0/910/1001/96
Acute coronary syndromeCardiac disorders0/910/1001/96
Chest painGeneral disorders0/910/1001/96
Most frequent other events
Showing 10 of 11
Most frequent other events
EventCarvedilol CRAtenololLisinopril
CoughRespiratory, thoracic and mediastinal disorders8/915/10016/96
FatigueGeneral disorders6/9116/1005/96
HeadacheNervous system disorders13/9111/10010/96
DizzinessNervous system disorders13/918/1006/96
NasopharyngitisInfections and infestations6/919/1008/96
DiarrheaGastrointestinal disorders5/917/1007/96
Upper respiratory tract infectionInfections and infestations5/913/1007/96
Edema peripheralGeneral disorders6/917/1005/96
DyspneaRespiratory, thoracic and mediastinal disorders3/917/1000/96
Muscle spasmsMusculoskeletal and connective tissue disorders6/913/1004/96

Baseline characteristics

Age, Continuous
Age, Continuous(years)Carvedilol CRAtenololLisinoprilTotal
Mean56.6 ± 10.5357.4 ± 10.9555.9 ± 10.0956.7 ± 10.52
Gender
Gender(Participants)Carvedilol CRAtenololLisinoprilTotal
Female404147128
Male515949159
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Carvedilol CRAtenololLisinoprilTotal
African American/African Heritage17261760
American Indian/Alaska Native0112
Asian2103
White/Caucasian676772206
Arabic/North African Heritage1012
Mixed Race1012
Not Reported35412
08

Study locations

78 sites
  • GSK Investigational Site
    Birmingham, Alabama 35235, United States
  • GSK Investigational Site
    Birmingham, Alabama 35249, United States
  • GSK Investigational Site
    Mobile, Alabama 36608, United States
  • GSK Investigational Site
    Chandler, Arizona 77030, United States
  • GSK Investigational Site
    Mesa, Arizona 85206, United States
  • GSK Investigational Site
    Peoria, Arizona 85381 - 4828, United States
  • GSK Investigational Site
    Scottsdale, Arizona 85251, United States
  • GSK Investigational Site
    Scottsdale, Arizona 85260, United States
  • GSK Investigational Site
    Sun City, Arizona 85351, United States
  • GSK Investigational Site
    Fresno, California 93720, United States
  • GSK Investigational Site
    Los Angeles, California 90033, United States
  • GSK Investigational Site
    Los Angeles, California 90048, United States
  • GSK Investigational Site
    Los Angeles, California 90095, United States
  • GSK Investigational Site
    Palo Alto, California 94301, United States
  • GSK Investigational Site
    Poway, California 92064, United States
  • GSK Investigational Site
    Sacremento, California 95819, United States
  • GSK Investigational Site
    San Diego, California 92120, United States
  • GSK Investigational Site
    San Leandro, California 94578, United States
  • GSK Investigational Site
    Santa Ana, California 92705, United States
  • GSK Investigational Site
    Colorado Springs, Colorado 80907, United States
  • GSK Investigational Site
    Colorado Springs, Colorado 80919, United States
  • GSK Investigational Site
    Denver, Colorado 80204, United States
  • GSK Investigational Site
    Denver, Colorado 80218, United States
  • GSK Investigational Site
    Newark, Delaware 19718, United States
  • GSK Investigational Site
    Washington, District of Columbia 20037, United States
  • GSK Investigational Site
    Washington, District of Columbia 20422, United States
  • GSK Investigational Site
    Altamonte Springs, Florida 32714, United States
  • GSK Investigational Site
    Atlantis, Florida 33462, United States
  • GSK Investigational Site
    Jacksonville, Florida 32209, United States
  • GSK Investigational Site
    Kissimmee, Florida 34741, United States
  • GSK Investigational Site
    Longwood, Florida 32779, United States
  • GSK Investigational Site
    Miami, Florida 33156, United States
  • GSK Investigational Site
    Ormond Beach, Florida 32714, United States
  • GSK Investigational Site
    Pembroke Pines, Florida 33029, United States
  • GSK Investigational Site
    Evanston, Illinois 60201, United States
  • GSK Investigational Site
    Vernon Hills, Illinois 60061, United States
  • GSK Investigational Site
    Fort Wayne, Indiana 46804, United States
  • GSK Investigational Site
    Indianapolis, Indiana 46202, United States
  • GSK Investigational Site
    Scarborough, Maine 04074, United States
  • GSK Investigational Site
    Baltimore, Maryland 21224, United States
  • GSK Investigational Site
    Columbia, Maryland 21044, United States
  • GSK Investigational Site
    Pikesville, Maryland 21215, United States
  • GSK Investigational Site
    Grand Rapids, Michigan 49525, United States
  • GSK Investigational Site
    Edina, Minnesota 55435, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55417, United States
  • GSK Investigational Site
    Camden, New Jersey 08103, United States
  • GSK Investigational Site
    Buffalo, New York 14215, United States
  • GSK Investigational Site
    New York, New York 10011, United States
  • GSK Investigational Site
    New York, New York 10021, United States
  • GSK Investigational Site
    New York, New York 10128, United States
  • GSK Investigational Site
    Williamsville, New York 14221, United States
  • GSK Investigational Site
    Fayetteville, North Carolina 28304, United States
  • GSK Investigational Site
    Greensboro, North Carolina 27401, United States
  • GSK Investigational Site
    Winston-Salem, North Carolina 27157, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45224, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45267, United States
  • GSK Investigational Site
    Cleveland, Ohio 44122, United States
  • GSK Investigational Site
    Hillsboro, Oregon 97123-4117, United States
  • GSK Investigational Site
    Portland, Oregon 97210, United States
  • GSK Investigational Site
    Allentown, Pennsylvania 18105, United States
  • GSK Investigational Site
    Camp Hill, Pennsylvania 17011, United States
  • GSK Investigational Site
    Doylestown, Pennsylvania 18901, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19140, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15212, United States
  • GSK Investigational Site
    West Grove, Pennsylvania 19390, United States
  • GSK Investigational Site
    Warwick, Rhode Island 02886, United States
  • GSK Investigational Site
    Columbia, South Carolina 29204, United States
  • GSK Investigational Site
    Greenville, South Carolina 29615, United States
  • GSK Investigational Site
    Greer, South Carolina 29651, United States
  • GSK Investigational Site
    Kingsport, Tennessee 37660, United States
  • GSK Investigational Site
    Knoxville, Tennessee 37920, United States
  • GSK Investigational Site
    Nashville, Tennessee 37205, United States
  • GSK Investigational Site
    Houston, Texas 77030, United States
  • GSK Investigational Site
    Danville, Virginia 24541, United States
  • GSK Investigational Site
    Roanoke, Virginia 24014, United States
  • GSK Investigational Site
    Springfield, Virginia 22151, United States
  • GSK Investigational Site
    Tacoma, Washington 98405, United States
  • GSK Investigational Site
    Milwaukee, Wisconsin 53215, United States
09

References and documents

Publications

  • Bakris GL, Tarka EA, Waterhouse B, Goulding MR, Madan A, Anderson KM, St John Sutton M, Miller AB, Reichek N. Cardiovascular risk factors in hypertension: rationale and design of studies to investigate the effects of controlled-release carvedilol on regression of left ventricular hypertrophy and lipid profile. Am J Cardiol. 2006 Oct 2;98(7A):46L-52L. doi: 10.1016/j.amjcard.2006.08.002. Epub 2006 Aug 28. Erratum In: Am J Cardiol. 2007 Aug 1;100(3):562. Am J Cardiol. 2007 Mar 15;99(6):878. St John Sutton, Martin [added]; Miller, Alan B [added]; Reichek, Nathaniel [added]. PubMed 17023232 ↗
  • Miller AB, Reichek N, St John Sutton M, Iyengar M, Henderson LS, Tarka EA, Bakris GL. Importance of blood pressure control in left ventricular mass regression. J Am Soc Hypertens. 2010 Nov-Dec;4(6):302-10. doi: 10.1016/j.jash.2010.09.003. Epub 2010 Oct 27. PubMed 20980215 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2005, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2009, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2005
First posted
Apr 14, 2005
Start
Jan 2005
Primary completionActual
Aug 2008
CompletionActual
Aug 2008
Results first posted
Nov 9, 2009
Last update
Dec 16, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00108082
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Apr 14, 2005
Start date
Jan 2005
Primary completion
Aug 2008
Completion
Aug 2008
Results posted
Nov 9, 2009
Last update
Dec 16, 2016

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisinopril

Start the discussion